New York, New York (PRWEB) April 29, 2014
As dozens of Tylenol lawsuits (http://www.tylenollawsuitclaims.com/)
continue to move forward in federal court, Bernstein Liebhard LLP notes that federal health regulators are once again warning doctors not to prescribe medications that contain more than 325 milligrams of acetaminophen, due to the risk of liver damage posed by such products. In a statement posted on its website on April 28th, the U.S. Food & Drug Administration (FDA) said that such medications are no longer considered safe and have been voluntarily withdrawn from the market. The agency also reminded pharmacists to stop dispensing high-dose prescription acetaminophen products, and to return any such medications they have in stock to the wholesaler or manufacturer.
“The renewal of this warning comes as Tylenol lawsuits that allege the over-the-counter products caused acetaminophen-induced liver damage continue to move forward. Because the FDA’s action only applies to prescription drugs, so-called “extra strength” Tylenol products that contain more than 325 milligrams of acetaminophen remain on the market,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The firm is offering free legal reviews to consumers who were allegedly harmed by a Tylenol-brand over-the-counter medication.
Tylenol and Liver Damage
According to a report from The Los Angeles Times, the FDA initially issued its warning regarding high-dose prescription acetaminophen products in January 2014. Acetaminophen overdose is now the most common cause of acute liver failure, as well as the second-most common cause of liver failure requiring transplantation in the U.S.*
In August 2013, Bloomberg.com reported that over-the-counter Extra Strength Tylenol caplets each contain 500 mg of acetaminophen, well over the new limits for prescription medications set by the FDA. That same month, Johnson & Johnson’s McNeil Consumer Healthcare unit announced that it would add new, more prominent warnings regarding the risk of liver damage to the labels of Tylenol-brand medications.**
Court documents indicate that more than 120 Tylenol lawsuits have been filed in the U.S. District Court, Eastern District of Pennsylvania on behalf of individuals who allegedly suffered liver damage from Tylenol products, even when the over-the-counter medications were used in accordance with label directions. Among other things, these lawsuits claim that Johnson & Johnson and McNeil failed to provide the public with adequate warnings regarding the association between Tylenol and liver damage. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)
Alleged victims of acetaminophen-induced liver damage caused by a Tylenol-brand over-the-counter product may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To find out more about filing a Tylenol lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.
*latimes.com/science/sciencenow/la-sci-sn-extra-strength-acetaminophen-fda-20140428,0,6108401.story, LA Times, April 28, 2014
**bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP